Development of a drug assay system with hepatitis C virus genome derived from a patient with acute hepatitis C

Kyoko Mori, Youki Ueda, Yasuo Ariumi, Hiromichi Dansako, Masanori Ikeda, Nobuyuki Kato

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We developed a new cell culture drug assay system (AH1R), in which genome-length hepatitis C virus (HCV) RNA (AH1 strain of genotype 1b derived from a patient with acute hepatitis C) efficiently replicates. By comparing the AH1R system with the OR6 assay system that we developed previously (O strain of genotype 1b derived from an HCV-positive blood donor), we demonstrated that the anti-HCV profiles of reagents including interferon-γ and cyclosporine A significantly differed between these assay systems. Furthermore, we found unexpectedly that rolipram, an anti-inflammatory drug, showed anti-HCV activity in the AH1R assay but not in the OR6 assay, suggesting that the anti-HCV activity of rolipram differs depending on the HCV strain. Taken together, these results suggest that the AH1R assay system is useful for the objective evaluation of anti-HCV reagents and for the discovery of different classes of anti-HCV reagents.

Original languageEnglish
Pages (from-to)374-381
Number of pages8
JournalVirus Genes
Volume44
Issue number3
DOIs
Publication statusPublished - Jun 2012

Keywords

  • Acute hepatitis C
  • Anti-HCV activity of rolipram
  • Anti-HCV drug assay system
  • HCV

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Virology

Fingerprint Dive into the research topics of 'Development of a drug assay system with hepatitis C virus genome derived from a patient with acute hepatitis C'. Together they form a unique fingerprint.

  • Cite this